Moderna Shares Rise After Melanoma Vaccine Study Selected for Prestigious ESMO Symposium
Moderna's stock surged nearly 9% after its Phase 3 melanoma vaccine study was selected for a Presidential Symposium at the European Society for Medical Oncology (ESMO) congress in October. The session is reserved for groundbreaking data, signaling strong market confidence in Moderna’s results without new efficacy details being released yet. Merck and BioNTech also saw modest gains of 1% and 2%, respectively, but analysts suggest the rally reflects a re-rating specific to Moderna rather than broad validation across mRNA oncology. The study involves an individualized neoantigen therapy combined with Merck’s pembrolizumab checkpoint inhibitor. The market is interpreting the high-profile slot as indicative of potentially transformative data from Moderna's trial, which could reshape melanoma treatment protocols and significantly impact its valuation.
Topics: biotech cancer immunotherapy mRNA vaccines stock market reaction